

**DESCRIPTION**

<b>Source</b>	Human embryonic kidney cell, HEK293-derived human TNF-alpha protein Val77-Leu233 Accession # P01375
<b>N-terminal Sequence Analysis</b>	Val77
<b>Predicted Molecular Mass</b>	17 kDa

**SPECIFICATIONS**


<b>SDS-PAGE</b>	14-18 kDa, under reducing conditions
<b>Activity</b>	Measured in a cytotoxicity assay using L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D. Matthews, N. and M.L. Neale (1987) in <i>Lymphokines and Interferons, A Practical Approach</i> . Clemens, M.J. <i>et al.</i> (eds): IRL Press. 221. The ED <sub>50</sub> for this effect is 20-100 pg/mL.
<b>Endotoxin Level</b>	<0.10 EU per 1 $\mu$ g of the protein by the LAL method.
<b>Purity</b>	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 500 $\mu$ g/mL in PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 3 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>


**DATA**

**Bioactivity**



Recombinant Human TNF- $\alpha$  (HEK293-expressed) (Catalog # 10291-TA) induces cytotoxicity in the L-929 mouse fibroblast cell line in the presence of the metabolic inhibitor actinomycin D. The ED<sub>50</sub> for this effect is 20-100 pg/mL.

**SDS-PAGE**



2  $\mu$ g/lane of Recombinant Human TNF-alpha (HEK293-expressed) (Catalog # 10291-TA) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 14-18 kDa.

**BACKGROUND**

Tumor necrosis factor alpha (TNF- $\alpha$ ), also known as cachectin and TNFSF2, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in inflammation, immune system development, apoptosis, and lipid metabolism (1, 2). Human TNF- $\alpha$  consists of a 35 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 177 aa extracellular domain (ECD) (3). Within the ECD, human TNF- $\alpha$  shares 97% aa sequence identity with rhesus and 71%-92% with bovine, canine, cotton rat, equine, feline, mouse, porcine, and rat TNF- $\alpha$ . TNF- $\alpha$  is produced by a wide variety of immune, epithelial, endothelial, and tumor cells (1, 2). TNF- $\alpha$  is assembled intracellularly to form a noncovalently linked homotrimer which is expressed on the cell surface (4). Cell surface TNF- $\alpha$  can induce the lysis of neighboring tumor cells and virus infected cells, and it can generate its own downstream cell signaling following ligation by soluble TNFR I (2, 5). Shedding of membrane bound TNF- $\alpha$  by TACE/ADAM17 releases the bioactive cytokine, a 55 kDa soluble trimer of the TNF- $\alpha$  extracellular domain (6-8). TNF- $\alpha$  binds the ubiquitous 55-60 kDa TNF RI (9, 10) and the hematopoietic cell-restricted 80 kDa TNF RII (11, 12), both of which are also expressed as homotrimers (1, 2, 13). Both type I and type II receptors bind TNF- $\alpha$  with comparable affinity (14), although only TNF RI contains a cytoplasmic death domain which triggers the activation of apoptosis. Soluble forms of both types of receptors are released and can neutralize the biological activity of TNF- $\alpha$  (15).

**References:**

1. Zelova, H. and J. Hosek (2013) *Inflamm. Res.* **62**:641.
2. Juhasz, K. *et al.* (2013) *Expert Rev. Clin. Immunol.* **9**:335.
3. Pennica, D. *et al.* (1984) *Nature* **312**:724.
4. Tang, P. *et al.* (1996) *Biochemistry* **35**:8216.
5. Perez, C. *et al.* (1990) *Cell* **63**:251.
6. Black, R.A. *et al.* (1997) *Nature* **385**:729.
7. Moss, M.L. *et al.* (1997) *Nature* **385**:733.
8. Gearing, A.J.H. *et al.* (1994) *Nature* **370**:555.
9. Schall, T.J. *et al.* (1990) *Cell* **61**:361.
10. Loetscher, H. *et al.* (1990) *Cell* **61**:351.
11. Dembic, Z. *et al.* (1990) *Cytokine* **2**:231.
12. Smith, C.A. *et al.* (1990) *Science* **248**:1019.
13. Loetscher, H. *et al.* (1991) *J. Biol. Chem.* **266**:18324.
14. Pinckard, J.K. *et al.* (1997) *J. Biol. Chem.* **272**:10784.
15. Engelmann, H. *et al.* (1990) *J. Biol. Chem.* **265**:1531.